Skip to main content
SpringerLink
Log in

Principaux immunosuppresseurs et complications spécifiques

  • Chapter
Maladies rares en médecine d’urgence

Part of the book series: Références en médecine d’urgence. Collection de la SFMU ((REFERMED))

  • 1187 Accesses

Résumé

Au cours de la plupart des pathologies auto-immunes ou inflammatoires systémiques, le traitement de fond de première intention est la corticothérapie. Dans certaines situations, les immunosuppresseurs et/ou les traitements immunomodulateurs sont justifiés d’emblée, le plus souvent en association aux corticoïdes; tandis qu’ils seront utilisés quelquefois en seconde intention en cas de corticodépendance ou d’échec des corticoïdes prescrits seuls par voie générale (tableau I).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Terrier B, Berezné A, Mouthon L (2008) Corticothérapie. In: Guillevin L SJ, Piette JC, Meyer O, eds. Maladies et syndromes systémiques. Paris, Flammarion Médecine-Sciences

    Google Scholar 

  2. Fardet L, Kassar A, Cabane J, Flahault A (2007) Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 30: 861–81

    Article  PubMed  CAS  Google Scholar 

  3. Stamp L, Roberts R, Kennedy M, Barclay M, O’Donnell J, Chapman P (2006) The use of low dose methotrexate in rheumatoid arthritis — are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother 60: 678–87

    Article  PubMed  CAS  Google Scholar 

  4. Kievit W, Fransen J, Oerlemans AJ et al. (2007) The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66: 1473–8

    Article  PubMed  CAS  Google Scholar 

  5. Bijlsma JW, Boers M, Saag KG, Furst DE (2003) Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 62: 1033–7

    Article  PubMed  CAS  Google Scholar 

  6. Curtis JJ, Galla JH, Woodford SY, Saykaly RJ, Luke RG (1981) Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. Am J Kidney Dis 1: 166–71

    PubMed  CAS  Google Scholar 

  7. Bussone G, Hachulla E, Sibilia J et al. (2009) Treatment of systemic autoimmune and inflammatory diseases with rituximab. Presse Med 38: 808–23

    Article  PubMed  Google Scholar 

  8. Gangappa S, Kokko KE, Carlson LM et al. (2008) Immune responsiveness and protective immunity after transplantation. Transpl Int 21: 293–303

    Article  PubMed  CAS  Google Scholar 

  9. Dennin RH, Schulz E, Sack K, Dalhoff K, Hoyer J (1985) Influence of immunosuppressive therapy with azathioprine and prednisolone on serum-immunoglobulin concentration in renal transplanted patients. Klin Wochenschr 63: 1110–6

    Article  PubMed  CAS  Google Scholar 

  10. Yazici Y (2007) Vasculitis update, 2007. Bull NYU Hosp Jt Dis 65: 212–4

    PubMed  Google Scholar 

  11. Cara CJ, Pena AS, Sans M et al. (2004) Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 10: RA247–54

    PubMed  CAS  Google Scholar 

  12. Wetzels JF (2004) Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth J Med 62: 347–52

    PubMed  CAS  Google Scholar 

  13. Carre-Pigeon F, Schubert B (2007) Female fertility preservation in autoimmune diseases: possibilities and practises in France. Gynecol Obstet Fertil 35: 853–60

    Article  PubMed  CAS  Google Scholar 

  14. Faurschou M, Sorensen IJ, Mellemkjaer L et al. (2008) Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100–5

    PubMed  CAS  Google Scholar 

  15. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362: 971–82

    Article  PubMed  CAS  Google Scholar 

  16. Pagnoux C, Mahr A, Hamidou MA et al. (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359: 2790–803

    Article  PubMed  CAS  Google Scholar 

  17. Wolfe F (1997) Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Clin Exp Rheumatol 15(Suppl 17): S75–81

    PubMed  Google Scholar 

  18. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO (1987) Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 16: 186–95

    Article  PubMed  CAS  Google Scholar 

  19. Kaltwasser JP, Behrens F (2005) Leflunomide: long-term clinical experience and new uses. Expert Opin Pharmacother 6: 787–801

    Article  PubMed  CAS  Google Scholar 

  20. Kyriakides G, Miller J (2004) Use of cyclosporine in renal transplantation. Transplant Proc 36(2 Suppl): 167S–72S

    Article  PubMed  CAS  Google Scholar 

  21. Iaccarino L, Arienti S, Rampudda M et al. (2007) Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability. Ann NY Acad Sci 1110: 516–24

    Article  PubMed  CAS  Google Scholar 

  22. Wang K, Zhang H, Li Y et al. (2004) Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 36: 2068–70

    Article  PubMed  CAS  Google Scholar 

  23. Feagans J, Victor D, Moehlen M et al. (2009) Interstitial pneumonitis in the transplant patient: consider sirolimus-associated pulmonary toxicity. J La State Med Soc 161:8–72

    Google Scholar 

  24. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–85

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de médecine interne, hôpital Cochin, 75014, Paris, France

    L. Mouthon

  2. Centre de Référence pour les vascularites nécrosantes et la sclérodermie systémique, AP-HP et Université Paris Descartes, Paris, France

    L. Mouthon

Authors
  1. L. Mouthon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Mouthon .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Mouthon, L. (2013). Principaux immunosuppresseurs et complications spécifiques. In: Maladies rares en médecine d’urgence. Références en médecine d’urgence. Collection de la SFMU. Springer, Paris. https://doi.org/10.1007/978-2-8178-0350-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0350-0_5

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0349-4

  • Online ISBN: 978-2-8178-0350-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation